FDA 483 - DOT Gmbh - November 16, 2023

During an FDA inspection conducted from November 13 to November 16, 2023, the manufacturing firm DOT Gmbh, located in Rostock, Germany, received a Form FDA 483 citing an significant observation related to its quality system. The primary issue identified was the inadequacy of procedures for receiving, reviewing, and evaluating complaints and nonconformances. Specifically, the firm's established procedure failed to sufficiently detail the required level of documentation for nonconformance reports. For instance, several nonconformance records, such as those related to "Traces of processing" issues and a "pump defect," did not adequately document the specific data reviewed for effectiveness checks or provide sufficient evidence, like test reports, to substantiate root cause investigations. These observations indicate a need for improvement in DOT Gmbh's adherence to quality system requirements, which are essential for ensuring product quality and patient safety. While the FDA 483 is an inspectional observation document, DOT Gmbh has acknowledged the observation and committed to implementing corrective actions. The company is expected to revise its procedures to ensure comprehensive documentation of complaint and nonconformance investigations and their effectiveness monitoring, thereby addressing the identified deficiencies in its quality management system.